GlassScriptPhysician profile
Shyam A Patel
NPI 1669815874
$24,362.55
in general payments reported to CMS, 2019-2025
17 companies · $9,003 in 2025
The $9,003 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2021: $4,430 · 2022: $3,275 · 2023: $3,496 · 2024: $4,019 · 2025: $9,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Travel and Lodging: $2,299 · Food and Beverage: $907 · Education: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,030.00 |
| Travel and Lodging | $2,298.90 |
| Food and Beverage | $907.07 |
| Education | $281.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,039.52 | 2022-2024 | |
| Celgene Corporation | $4,929.25 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $4,843.26 | 2025 | Revuforj |
| Taiho Oncology, INC. | $2,463.46 | 2025 | |
| Pfizer INC. | $1,765.00 | 2021 | |
| Rigel Pharmaceuticals, INC. | $1,500.00 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Sanofi-Aventis U.S. LLC | $185.94 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $121.14 | 2019 | |
| Medtronic, INC. | $104.74 | 2024 | Infinity Occipitocervical Upper Thoracic System |
| Incyte Corporation | $99.99 | 2025 | |
| Epizyme, INC. | $99.95 | 2021 | |
| Seagen INC. | $95.95 | 2025 | |
| Sun Pharmaceutical Industries INC. | $42.12 | 2021-2022 | |
| Kite Pharma, INC. | $38.83 | 2024 | Yescarta |
| Janssen Pharmaceuticals, INC | $18.75 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $14.65 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shyam Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.